Page last updated: 2024-12-11

1-formylisoquinoline thiosemicarbazone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

## 1-Formylisoquinoline Thiosemicarbazone (1-FIQ)

1-Formylisoquinoline thiosemicarbazone (1-FIQ) is a **heterocyclic compound** with a **thiosemicarbazone** functional group attached to an isoquinoline ring. Its structure contains both **nitrogen** and **sulfur** atoms, making it a potential **chelating agent** for various metals.

**Importance in Research:**

1-FIQ has gained significant attention in research due to its promising biological activities, particularly:

* **Anti-cancer properties:** 1-FIQ exhibits significant **anti-proliferative** and **anti-tumor** activities against various cancer cell lines, including leukemia, lung, breast, and prostate cancers. Its mechanism of action involves inhibiting the growth of cancer cells by **inducing apoptosis** and **arresting cell cycle progression**.

* **Anti-viral properties:** Studies have shown that 1-FIQ demonstrates **antiviral activity** against a wide range of viruses, including **HIV**, **influenza**, and **herpes simplex virus**. It achieves this by inhibiting the replication of these viruses.

* **Anti-parasitic properties:** 1-FIQ has shown **anti-parasitic activity** against various protozoa, such as **malaria** and **toxoplasmosis**.

* **Anti-inflammatory properties:** 1-FIQ has been shown to possess **anti-inflammatory** properties, likely due to its ability to **inhibit the production of inflammatory mediators**.

**Research Directions:**

Current research efforts are focused on:

* **Understanding the mechanism of action** of 1-FIQ in different biological systems to enhance its effectiveness and minimize potential side effects.
* **Developing novel derivatives** of 1-FIQ with improved potency and selectivity for specific therapeutic targets.
* **Evaluating the potential of 1-FIQ** as a therapeutic agent for various diseases, including cancer, viral infections, and parasitic infections.
* **Exploring the potential of 1-FIQ** as a lead compound for the development of new drugs with improved efficacy and safety profiles.

**Overall, 1-FIQ represents a promising therapeutic candidate with a wide range of potential applications in various medical fields. Further research on its pharmacological properties and clinical trials are necessary to fully realize its therapeutic potential.**

1-formylisoquinoline thiosemicarbazone: structure; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5874389
CHEMBL ID1976175
MeSH IDM0043159

Synonyms (13)

Synonym
isoquinaldehyde thiosemicarbazone
nsc 92188
ai3-51873
2-(1-isoquinolinylmethylene)hydrazinecarbothioamide
[(z)-1-isoquinolylmethyleneamino]thiourea
1-formylisoquinoline thiosemicarbazone
isoquinaldaldehyde, thiosemicarbazone
61043-13-8
mls002702043 ,
nsc-162700
nsc162700
[(z)-isoquinolin-1-ylmethylideneamino]thiourea
CHEMBL1976175
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (85.71)18.7374
1990's1 (14.29)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.21 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (42.86%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (57.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]